DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for transient myeloproliferative syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTransient myeloproliferative syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for transient myeloproliferative syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Transient myeloproliferative disorder (TMD) occurs in newborns with Down syndrome, whether well or ill. For most infants the process is relatively harmless, but in some children it presents as a life-threatening state requiring critical care. The 2012 article states the disease is seemingly uncommon and aims to discuss common presentations, diagnosis, and management, but provides no patient numbers, survival data, or response rates. No drug is mentioned in that abstract.
A 2007 review describes the broader myeloproliferative syndromes — chronic myelogenous leukaemia, polycythaemia vera, essential thrombocythaemia, and idiopathic myelofibrosis — as clonal myeloid stem cell disorders with autonomous proliferation and overproduction of one or more haematopoietic cell lineages. That abstract does not address TMD and offers no drug information.
A 2012 article on acute myeloproliferative disease notes it is a heterogeneous group of malignant disorders with recurrent genetic abnormalities including t(15;17), t(8;21), inv(16)/t(16;16), and mutations in NPM1, FLT3, and CEBPA. It states these aberrant proteins have become targets for drug development intended to improve therapy efficacy and diminish toxicity, but gives no drug names, trial results, or survival figures.
No evidence from these abstracts supports any specific drug for transient myeloproliferative syndrome. What is missing is any prospective trial designed for TMD, any patient stratification by genetic markers in that population, and the funding needed to study a condition that, while sometimes life-threatening, is uncommon enough that providers may lack urgency in recognising it.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Pediatric Oncology Nursing · 2012 · 0 citations
Transient Myeloproliferative Disease
AbstractTransient myeloproliferative disorder (TMD) can be found in well or ill newborns with Down syndrome. Although it is a relatively harmless process for most, in some children, TMD can present as a life-threatening state requiring critical care. As the disease is seemingly uncommon, some providers may lack a sense of urgency in the dissemination of TMD awareness; however, one can never know on whose door this patient may knock tomorrow. Advanced practice professionals should be prepared for the TMD patient that may present without warning. The goals of this article are to discuss common presentations, diagnosis, and management; and to bring attention to this often de-emphasized disease.
AbstractThe myeloproliferative syndromes encompass four major clinical entities: chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IM). These disorders are clonal myeloid stem cell disorders characterized by the autonomous proliferation of the clone, which results in the overproduction of one or more hematopoietic cell lineages. The clinical presentation and natural history of each disorder is distinct, but the features of the disorders often overlap (e.g., CML with myelo-fibrosis or PV with thrombocytosis).
AbstractAcute myeloproliferative disease is a heterogeneous group of malignant disorders. In spite of the great variability regarding genetic and clinical aspects, all forms present common mechanisms underlying their pathogenesis: the disruption of genes tightly involved in the control of cell differentiation, proliferation and/or apoptosis. Major progress has been made to better understand such events and recurrent genetic abnormalities have been acknowledged based on both physiopathologic and prognostic relevance: t(15;17), t(8;21), inv(16)/t(16;16), in addition to mutations in the genes NPM1, FLT3 and CEBPA. These genetic alterations have identified particular subgroups of patients and their resultant aberrant proteins have become targets for drug development, intending to improve therapy efficacy and to diminish its toxicity.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
